US Patent 10,278,969: Claim Scope, Exclusivity, and Patent Landscape for the Mono-Phosphate Capsule Formulation

US Patent 10,278,969 protects an oral capsule containing a specific kinase-inhibitor compound in mono-phosphate salt form, together with hydroxypropylmethylcellulose, crosslinked polyvinylpyrrolidone, and a defined filler. The patent is a formulation patent, not a broad composition-of-matter patent. Its commercial value depends on whether the claimed drug substance is marketed, whether the patent is listed in the FDA Orange Book, and whether competing products use the claimed excipient ranges and density limitations.

The independent claim requires all of the following:

An oral capsule.
A pharmaceutical blend encapsulated in the capsule.
The specified drug substance in mono-phosphate salt form.
Drug substance content of 20% to 60% by weight.
Hydroxypropylmethylcellulose content of 0.5% to 5%.
Crosslinked polyvinylpyrrolidone content of 1% to 4%.
A filler selected from cellulose, lactose, mannitol, or combinations.
Weight percentages calculated against the total pharmaceutical-blend content.

Claims 2 through 4 add bulk-density and narrower concentration limitations. The claims do not, on their face, cover the active pharmaceutical ingredient in all dosage forms, all salts, or all formulations.

What does US Patent 10,278,969 protect?

The patent protects a specific oral solid dosage formulation containing the identified pharmaceutical compound as a mono-phosphate salt.

The active ingredient is chemically identified as:

3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea

The protected formulation uses three functional formulation components:

Component	Claim 1 range	Function in formulation
Active mono-phosphate salt	20% to 60%	Therapeutic ingredient
Hydroxypropylmethylcellulose	0.5% to 5%	Binder, matrix former, or release-modifying excipient
Crosslinked polyvinylpyrrolidone	1% to 4%	Superdisintegrant
Filler	Unspecified balance	Cellulose, lactose, mannitol, or combinations

The use of "comprising" makes the claim open-ended. An accused capsule may contain additional excipients and still fall within the claim if it retains every required component and concentration limitation.

The patent does not require a particular capsule shell, capsule size, manufacturing process, dissolution profile, particle size, or release profile in claim 1.

How should the active ingredient limitation be interpreted?

The active-ingredient limitation is unusually narrow.

The claim does not cover:

The free base by itself.
A different salt, such as hydrochloride, sulfate, mesylate, or citrate.
A solvate or co-crystal that does not qualify as the claimed mono-phosphate salt.
A structurally related kinase inhibitor.
A formulation containing the same molecule at less than 20% or more than 60% of blend weight.

The phrase "in its free base form, present as mono-phosphate salt" should be read with the specification and prosecution history. Chemically, the wording appears intended to identify the mono-phosphate salt of the stated free-base molecule. The relevant issue is whether the salt has a one-to-one stoichiometric relationship between the basic drug molecule and phosphoric acid, rather than a different phosphate stoichiometry or a non-salt solid form.

For infringement analysis, analytical characterization would likely focus on:

Molecular identity of the active moiety.
Salt stoichiometry.
Water or solvent content.
Whether the product contains the claimed phosphate form rather than a mixture of forms.
Actual formulation weight percentages.

What are the concentration limitations in claim 1?

Claim 1 requires the active mono-phosphate salt to constitute 20% to 60% by weight of the pharmaceutical blend. The excipient ranges are:

Hydroxypropylmethylcellulose: 0.5% to 5%.
Crosslinked polyvinylpyrrolidone: 1% to 4%.

Because the percentages are based on the total pharmaceutical-blend content, the capsule shell is excluded from the calculation. The relevant denominator is the total weight of the blend inside the capsule.

For example, a blend containing 40 mg of active salt, 3 mg of hydroxypropylmethylcellulose, 3 mg of crosslinked polyvinylpyrrolidone, and 54 mg of filler would contain:

Active salt: 40%.
Hydroxypropylmethylcellulose: 3%.
Crosslinked polyvinylpyrrolidone: 3%.
Filler: 54%.

That formulation would fall within the numerical ranges of claim 1, assuming the active ingredient is the claimed mono-phosphate salt.

The claim does not specify whether percentages must be measured from theoretical formulation quantities or finished-product assay results. That issue would be relevant in an infringement dispute, particularly where manufacturing variability moves a component close to a claim boundary.

What does claim 2 add?

Claim 2 requires the pharmaceutical blend to have a poured bulk density of at least 0.4 g/mL.

This limitation narrows claim 1 to blends with sufficient bulk density for capsule filling and handling. It may also distinguish formulations that require excessive capsule volume or produce poor weight uniformity.

A density of at least 0.4 g/mL is not a mere compositional limitation. It is a physical-property limitation. Enforcement would require a reproducible testing method, including:

Equipment and container dimensions.
Sample conditioning.
Powder handling.
Pouring procedure.
Tapping or absence of tapping.
Replicate measurements.
Temperature and humidity.

"Poured bulk density" generally differs from tapped density. A formulation that reaches 0.4 g/mL only after tapping should not automatically satisfy claim 2.

What does claim 3 add?

Claim 3 limits the active drug content to 30% to 45% by weight.

This range is narrower than claim 1 and is wholly contained within the 20% to 60% range. A formulation containing 30% to 45% active salt can potentially infringe both claims 1 and 3, provided the other limitations are met.

Claim 3 excludes formulations containing:

More than 45% active salt.
Less than 30% active salt.

It does not independently require any particular bulk density.

What does claim 4 add?

Claim 4 depends on claim 3 and requires:

Active mono-phosphate salt: 30% to 45%.
Hydroxypropylmethylcellulose: 2% to 4%.
Crosslinked polyvinylpyrrolidone: 2% to 4%.

Claim 4 is the narrowest express formulation claim in the supplied claim set. It is likely directed to a preferred composition window that balances drug loading, capsule volume, binding, disintegration, and powder flow.

A formulation with 35% active salt, 3% hydroxypropylmethylcellulose, and 3% crosslinked polyvinylpyrrolidone would meet the numerical limitations of claim 4. The filler would make up the remaining blend weight, subject to the requirement that it be cellulose, lactose, mannitol, or a combination.

How many patents cover the formulation?

The supplied claims establish one patent family member with a formulation claim set. They do not establish the number of related US or foreign patents.

A complete patent-landscape assessment would separate the following categories:

Patent category	Relevance to this formulation
Composition-of-matter patents	May cover the active molecule or its broad chemical genus
Salt and polymorph patents	May cover the mono-phosphate salt, crystalline forms, hydrates, or solvates
Formulation patents	May cover the capsule composition claimed in US 10,278,969
Manufacturing patents	May cover granulation, blending, milling, encapsulation, or scale-up
Method-of-use patents	May cover treatment indications and dosing regimens
Combination patents	May cover use with another oncology agent
Device or delivery patents	Relevant only if the capsule is combined with a specialized delivery system

US 10,278,969 should therefore be treated as one layer of a potentially broader patent estate. The claims supplied do not demonstrate ownership of the active ingredient, exclusivity over other salts, or exclusivity over therapeutic use.

What is the patent expiration date?

The expiration date cannot be calculated from the issued patent number or claims alone. US patent term generally runs 20 years from the earliest effective nonprovisional US filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and relevant priority claims (35 U.S.C. §§ 154, 156).

For a commercial freedom-to-operate analysis, the controlling records are:

The patent front page.
The earliest effective US nonprovisional filing date.
Any terminal disclaimer.
USPTO patent-term-adjustment data.
Any Hatch-Waxman patent-term extension.
Continuation and divisional relationships.
Maintenance-fee status.

The issue date of US 10,278,969 does not itself determine the expiration date.

Is US Patent 10,278,969 listed in the Orange Book?

A patent is not automatically Orange Book-listed merely because it claims a drug formulation. FDA listing depends on the approved drug product, the NDA holder, the relationship between the patent claims and the approved product, and the sponsor's certification to FDA.

The patent number and claims supplied do not identify:

A USAN or INN name for the active compound.
A marketed brand.
An approved NDA.
An NDA holder.
An FDA-approved dosage strength.
An Orange Book product entry.

Accordingly, the claim text alone does not establish an Orange Book listing. If the active compound has not received FDA approval, the patent would generally have no operative Orange Book role, even though it could still support ordinary patent litigation against an unapproved commercial product.

FDA's Orange Book identifies patents submitted for approved drug products and related exclusivity information, but it is not a complete database of pharmaceutical patents (FDA, 2024).

Are Paragraph IV challenges relevant?

Paragraph IV litigation is relevant only if:

The active compound is the subject of an approved NDA.
US 10,278,969 is listed against that NDA.
A generic applicant submits an ANDA referencing the listed product.
The ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.

If those conditions exist, a Paragraph IV notice could create a patent litigation pathway under the Hatch-Waxman Act. The patentee or NDA holder generally has 45 days to file an infringement action, which can trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions (21 U.S.C. § 355(j)(2)(A)(vii)(IV); § 355(j)(5)(B)(iii)).

For this claim set, a generic challenger could attack the patent through several routes:

The active product uses a different salt.
The active concentration falls outside 20% to 60%.
Hydroxypropylmethylcellulose falls outside 0.5% to 5%.
Crosslinked polyvinylpyrrolidone falls outside 1% to 4%.
The filler is not cellulose, lactose, mannitol, or a combination.
The product is not a capsule.
The blend density is below 0.4 g/mL for claim 2.
The claimed ranges are anticipated or obvious.
The patent's written description does not adequately support the full ranges.
The salt or formulation terminology is indefinite.

How strong is the patent estate?

Strengths

The formulation claims have several practical strengths:

Claim 1 combines the active identity, salt form, dosage form, and excipient ranges.
The active chemical definition is highly specific.
The ranges may be difficult to avoid if a development program reproduces the claimed formulation.
The open "comprising" language permits additional excipients.
Claims 2 and 4 provide fallback positions with narrower technical limitations.
The density limitation may capture manufacturing-equivalent formulations even where excipient amounts vary within the broad claim.

Vulnerabilities

The same specificity creates design-around and validity risks:

A competitor can select a different salt.
A competitor can move one excipient just outside the claimed range.
A competitor can replace hydroxypropylmethylcellulose with another binder.
A competitor can replace crosslinked polyvinylpyrrolidone with another disintegrant.
A competitor can use a tablet, sachet, suspension, or softgel rather than the claimed capsule.
A competitor can use a filler outside the listed Markush group.
Prior-art formulation examples may challenge novelty or obviousness.
The claim does not require a demonstrated dissolution, stability, bioavailability, or therapeutic advantage unless such limitations appear elsewhere in the patent.

The broadest practical protection is claim 1. Claim 4 is narrower but may be more defensible if the specification provides comparative data supporting the selected ranges.

What generic launch risks exist?

At-risk launch

A generic manufacturer could launch before patent expiry after a Paragraph IV certification, accepting exposure to infringement damages and injunctive relief. This strategy depends on the patent's listing status, litigation outcome, and commercial value of the reference product.

Non-infringing launch

A generic could seek approval with a formulation that changes one or more claim elements. The most direct routes are:

Design-around route	Principal risk
Use a non-phosphate salt	Salt characterization and equivalence disputes
Use active content below 20% or above 60%	Dose strength and capsule size constraints
Replace hydroxypropylmethylcellulose	Bioequivalence and release-profile risk
Replace crosslinked polyvinylpyrrolidone	Disintegration and dissolution risk
Use a non-listed filler	Manufacturing and regulatory comparability
Use a tablet or other dosage form	Product-specific bioequivalence requirements
Alter blend density below 0.4 g/mL	Capsule-volume and weight-uniformity problems

A design-around that changes only the density may avoid claim 2 but would not avoid claim 1 or claims 3 and 4.

What manufacturing and IP barriers does the patent create?

The patent may affect more than ingredient selection. A commercial product must reproduce a manufacturable powder blend with acceptable:

Content uniformity.
Flowability.
Encapsulation performance.
Disintegration.
Dissolution.
Chemical stability.
Moisture control.
Scale-up performance.

The 0.4 g/mL density limitation suggests that capsule volume and powder packing were important development constraints. A competitor may avoid literal infringement by using a different formulation, but that alternative may require a larger capsule, a different dose strength, additional granulation, or a separate bioequivalence program.

The patent does not appear, from the supplied claims, to claim a particular manufacturing process. Process patents, if present elsewhere in the family or portfolio, could create separate infringement risks even when a formulation avoids US 10,278,969.

Does the patent create biosimilar risk?

No. Biosimilar law applies to biological products, not a conventional small-molecule kinase-inhibitor capsule. The relevant competitive threat would be an ANDA generic, a 505(b)(2) applicant, or an independent innovator product, not a biosimilar.

A 505(b)(2) applicant could be relevant if it uses a different salt, dosage form, strength, or formulation while relying in part on FDA findings for a listed product. Whether that route is available depends on FDA approval history and the active ingredient's regulatory status.

What licensing or settlement issues should be reviewed?

The claim set does not establish any licensing deal or settlement agreement. A complete diligence review should examine:

Assignment records.
Exclusive-license filings.
Royalty obligations.
Development and commercialization agreements.
Paragraph IV notices.
Infringement complaints.
Consent judgments.
Settlement agreements.
Authorized-generic provisions.
Covenants not to sue.
Patent-term-extension applications.

A settlement can materially alter launch timing even when a patent remains unexpired. Conversely, an unlisted formulation patent may have limited Hatch-Waxman leverage but retain value in a conventional infringement action.

Key Takeaways

US 10,278,969 is directed to a specific oral capsule formulation.
It does not, based on the supplied claims, broadly claim the drug molecule, all salts, or all therapeutic uses.
Claim 1 requires the stated mono-phosphate salt, three excipient categories, specified concentration ranges, and an oral capsule.
Claim 2 adds a poured bulk-density threshold of at least 0.4 g/mL.
Claim 3 narrows the active concentration to 30% to 45%.
Claim 4 narrows the binder and disintegrant ranges to 2% to 4% each.
The principal design-around options are a different salt, dosage form, binder, disintegrant, filler, or active-loading range.
Biosimilar risk is not applicable because the claimed product is a small-molecule formulation.
Orange Book status, patent expiration, Paragraph IV exposure, litigation, licensing, and settlement status cannot be established from the claim text alone.
The patent's commercial strength depends on whether the claimed formulation corresponds to an approved and commercially important product.

FAQs

Can a tablet infringe US Patent 10,278,969?

The supplied claims require a capsule for oral administration. A tablet would not literally satisfy the capsule limitation, although other patents in the same portfolio could cover the tablet formulation.

Does using the free base avoid the patent?

Not necessarily in every legal theory, but it would avoid the express mono-phosphate-salt limitation of the supplied claims if the product contains only the uncharged free base.

Can a formulation use crospovidone at 4.1%?

A formulation containing 4.1% crosslinked polyvinylpyrrolidone would fall outside the literal 1% to 4% limitation in claims 1 and 3, subject to measurement methodology and any doctrine-of-equivalents analysis.

Does a formulation with 25% active ingredient infringe claim 3?

No. It may fall within claim 1's 20% to 60% active range, but it would not meet claim 3's narrower 30% to 45% range.

Does a different cellulose filler avoid the patent?

Not automatically. Claim 1 expressly includes "a cellulose," which is broad enough to cover many cellulose fillers. The specific identity and regulatory grade of the cellulose would require claim-construction analysis.

References

United States Patent No. 10,278,969, claims 1-4. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Code, 35 U.S.C. § 154. Patent term.
United States Code, 35 U.S.C. § 156. Extension of patent term.
United States Code, 21 U.S.C. § 355. New drug applications and abbreviated applications.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-001	May 28, 2021		DISCN	Yes	No	10,278,969	⤷ Start Trial	Y				⤷ Start Trial
Helsinn Hlthcare	TRUSELTIQ	infigratinib phosphate	CAPSULE;ORAL	214622-002	May 28, 2021		DISCN	Yes	No	10,278,969	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	December 11, 2014	PCT Application Number:	PCT/IB2014/066820
PCT Publication Date:	June 18, 2015	PCT Publication Number:	WO2015/087283

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	098716	⤷ Start Trial
Australia	2014362999	⤷ Start Trial
Canada	2930055	⤷ Start Trial
Chile	2016001436	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,278,969

Which drugs does patent 10,278,969 protect, and when does it expire?

Summary for Patent: 10,278,969